News|Videos|September 21, 2023

CHRYSALIS-2: Amivantamab + Lazertinib in Non–Small Cell Lung Cancer

Key opinion leaders review data from the CHRYSALIS-2 trial and consider the optimal utilization of amivantamab and lazertinib in combination in the setting of non–small cell lung cancer management.


Latest CME